Structural and functional neuroprotection in a rat model of Huntington's disease by viral gene transfer of GDNF

Jodi McBride, Matthew J. During, Joanne Wuu, Er Yun Chen, Sue E. Leurgans, Jeffrey H. Kordower

Research output: Contribution to journalArticle

74 Citations (Scopus)

Abstract

Huntington's disease (HD) is an autosomal dominant disorder caused by an expanded polyglutamine (CAG) tract at the IT15 locus on chromosome 4. These excessive repeats lead to the degeneration of striatal and cortical neurons resulting in a devastating cognitive, psychiatric, and motor disorder for which no treatments are available. Neurotrophic factors support the viability of striatal neurons suggesting that they might prevent the inevitable neural degeneration and its accompanying functional decline associated with HD. The present study investigated whether glial cell line-derived neurotrophic factor (GDNF) delivered by an adeno associated virus could provide structural and functional neuroprotection in a rat model of HD. Lewis rats received bilateral injections of either AAV-GDNF (n = 12) or AAV-green fluorescence protein (AAV-GFP, n = 12) into the striatum followed 2 weeks later by chronic subcutaneous infusions of the mitochondrial toxin, 3-nitropropionic acid (3-NP, 38 mg/kg). All rats underwent 4 weeks of behavioral testing and were then sacrificed. Following 3-NP, the performance by AAV-GFP-treated rats on a raised platform motor task deteriorated while the performance by AAV-GDNF-treated rats was near normal (P <0.001). AAV-GDNF-treated rats also received better scores on a blinded semi-quantitative neurological scale compared to rats receiving AAV-GFP (P <0.001). Histological analyses supported our behavioral findings. 3-NP-treated rats receiving AAV-GDNF displayed 70% more NeuN-immunoreactive neurons compared to 3-NP-treated rats receiving AAV-GFP (P = 0.002). Similar findings were seen with dopamine-and-adenosine-3′5′-monophosphate-regulated phosphoprotein (DARPP-32) staining. These data indicate that the viral-mediated gene transfer of GDNF into the striatum provides neuroanatomical and behavioral protection in a rodent model of HD.

Original languageEnglish (US)
Pages (from-to)213-223
Number of pages11
JournalExperimental Neurology
Volume181
Issue number2
DOIs
StatePublished - Jun 1 2003
Externally publishedYes

Fingerprint

Glial Cell Line-Derived Neurotrophic Factor
Viral Genes
Huntington Disease
Corpus Striatum
Neurons
Subcutaneous Infusions
Dependovirus
Chromosomes, Human, Pair 4
Phosphoproteins
Nerve Growth Factors
Adenosine Monophosphate
Neuroprotection
Psychiatry
Rodentia
Dopamine
Fluorescence
Staining and Labeling
Injections

Keywords

  • 3-Nitropropionic acid
  • Adenoassociated viral vector
  • Gene therapy
  • Glial cell line-derived neurotrophic factor
  • Huntington's disease
  • Rat

ASJC Scopus subject areas

  • Neurology
  • Neuroscience(all)

Cite this

Structural and functional neuroprotection in a rat model of Huntington's disease by viral gene transfer of GDNF. / McBride, Jodi; During, Matthew J.; Wuu, Joanne; Chen, Er Yun; Leurgans, Sue E.; Kordower, Jeffrey H.

In: Experimental Neurology, Vol. 181, No. 2, 01.06.2003, p. 213-223.

Research output: Contribution to journalArticle

McBride, Jodi ; During, Matthew J. ; Wuu, Joanne ; Chen, Er Yun ; Leurgans, Sue E. ; Kordower, Jeffrey H. / Structural and functional neuroprotection in a rat model of Huntington's disease by viral gene transfer of GDNF. In: Experimental Neurology. 2003 ; Vol. 181, No. 2. pp. 213-223.
@article{2d65ebea98e347179ff4d4422ab24a43,
title = "Structural and functional neuroprotection in a rat model of Huntington's disease by viral gene transfer of GDNF",
abstract = "Huntington's disease (HD) is an autosomal dominant disorder caused by an expanded polyglutamine (CAG) tract at the IT15 locus on chromosome 4. These excessive repeats lead to the degeneration of striatal and cortical neurons resulting in a devastating cognitive, psychiatric, and motor disorder for which no treatments are available. Neurotrophic factors support the viability of striatal neurons suggesting that they might prevent the inevitable neural degeneration and its accompanying functional decline associated with HD. The present study investigated whether glial cell line-derived neurotrophic factor (GDNF) delivered by an adeno associated virus could provide structural and functional neuroprotection in a rat model of HD. Lewis rats received bilateral injections of either AAV-GDNF (n = 12) or AAV-green fluorescence protein (AAV-GFP, n = 12) into the striatum followed 2 weeks later by chronic subcutaneous infusions of the mitochondrial toxin, 3-nitropropionic acid (3-NP, 38 mg/kg). All rats underwent 4 weeks of behavioral testing and were then sacrificed. Following 3-NP, the performance by AAV-GFP-treated rats on a raised platform motor task deteriorated while the performance by AAV-GDNF-treated rats was near normal (P <0.001). AAV-GDNF-treated rats also received better scores on a blinded semi-quantitative neurological scale compared to rats receiving AAV-GFP (P <0.001). Histological analyses supported our behavioral findings. 3-NP-treated rats receiving AAV-GDNF displayed 70{\%} more NeuN-immunoreactive neurons compared to 3-NP-treated rats receiving AAV-GFP (P = 0.002). Similar findings were seen with dopamine-and-adenosine-3′5′-monophosphate-regulated phosphoprotein (DARPP-32) staining. These data indicate that the viral-mediated gene transfer of GDNF into the striatum provides neuroanatomical and behavioral protection in a rodent model of HD.",
keywords = "3-Nitropropionic acid, Adenoassociated viral vector, Gene therapy, Glial cell line-derived neurotrophic factor, Huntington's disease, Rat",
author = "Jodi McBride and During, {Matthew J.} and Joanne Wuu and Chen, {Er Yun} and Leurgans, {Sue E.} and Kordower, {Jeffrey H.}",
year = "2003",
month = "6",
day = "1",
doi = "10.1016/S0014-4886(03)00044-X",
language = "English (US)",
volume = "181",
pages = "213--223",
journal = "Experimental Neurology",
issn = "0014-4886",
publisher = "Academic Press Inc.",
number = "2",

}

TY - JOUR

T1 - Structural and functional neuroprotection in a rat model of Huntington's disease by viral gene transfer of GDNF

AU - McBride, Jodi

AU - During, Matthew J.

AU - Wuu, Joanne

AU - Chen, Er Yun

AU - Leurgans, Sue E.

AU - Kordower, Jeffrey H.

PY - 2003/6/1

Y1 - 2003/6/1

N2 - Huntington's disease (HD) is an autosomal dominant disorder caused by an expanded polyglutamine (CAG) tract at the IT15 locus on chromosome 4. These excessive repeats lead to the degeneration of striatal and cortical neurons resulting in a devastating cognitive, psychiatric, and motor disorder for which no treatments are available. Neurotrophic factors support the viability of striatal neurons suggesting that they might prevent the inevitable neural degeneration and its accompanying functional decline associated with HD. The present study investigated whether glial cell line-derived neurotrophic factor (GDNF) delivered by an adeno associated virus could provide structural and functional neuroprotection in a rat model of HD. Lewis rats received bilateral injections of either AAV-GDNF (n = 12) or AAV-green fluorescence protein (AAV-GFP, n = 12) into the striatum followed 2 weeks later by chronic subcutaneous infusions of the mitochondrial toxin, 3-nitropropionic acid (3-NP, 38 mg/kg). All rats underwent 4 weeks of behavioral testing and were then sacrificed. Following 3-NP, the performance by AAV-GFP-treated rats on a raised platform motor task deteriorated while the performance by AAV-GDNF-treated rats was near normal (P <0.001). AAV-GDNF-treated rats also received better scores on a blinded semi-quantitative neurological scale compared to rats receiving AAV-GFP (P <0.001). Histological analyses supported our behavioral findings. 3-NP-treated rats receiving AAV-GDNF displayed 70% more NeuN-immunoreactive neurons compared to 3-NP-treated rats receiving AAV-GFP (P = 0.002). Similar findings were seen with dopamine-and-adenosine-3′5′-monophosphate-regulated phosphoprotein (DARPP-32) staining. These data indicate that the viral-mediated gene transfer of GDNF into the striatum provides neuroanatomical and behavioral protection in a rodent model of HD.

AB - Huntington's disease (HD) is an autosomal dominant disorder caused by an expanded polyglutamine (CAG) tract at the IT15 locus on chromosome 4. These excessive repeats lead to the degeneration of striatal and cortical neurons resulting in a devastating cognitive, psychiatric, and motor disorder for which no treatments are available. Neurotrophic factors support the viability of striatal neurons suggesting that they might prevent the inevitable neural degeneration and its accompanying functional decline associated with HD. The present study investigated whether glial cell line-derived neurotrophic factor (GDNF) delivered by an adeno associated virus could provide structural and functional neuroprotection in a rat model of HD. Lewis rats received bilateral injections of either AAV-GDNF (n = 12) or AAV-green fluorescence protein (AAV-GFP, n = 12) into the striatum followed 2 weeks later by chronic subcutaneous infusions of the mitochondrial toxin, 3-nitropropionic acid (3-NP, 38 mg/kg). All rats underwent 4 weeks of behavioral testing and were then sacrificed. Following 3-NP, the performance by AAV-GFP-treated rats on a raised platform motor task deteriorated while the performance by AAV-GDNF-treated rats was near normal (P <0.001). AAV-GDNF-treated rats also received better scores on a blinded semi-quantitative neurological scale compared to rats receiving AAV-GFP (P <0.001). Histological analyses supported our behavioral findings. 3-NP-treated rats receiving AAV-GDNF displayed 70% more NeuN-immunoreactive neurons compared to 3-NP-treated rats receiving AAV-GFP (P = 0.002). Similar findings were seen with dopamine-and-adenosine-3′5′-monophosphate-regulated phosphoprotein (DARPP-32) staining. These data indicate that the viral-mediated gene transfer of GDNF into the striatum provides neuroanatomical and behavioral protection in a rodent model of HD.

KW - 3-Nitropropionic acid

KW - Adenoassociated viral vector

KW - Gene therapy

KW - Glial cell line-derived neurotrophic factor

KW - Huntington's disease

KW - Rat

UR - http://www.scopus.com/inward/record.url?scp=0037762555&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0037762555&partnerID=8YFLogxK

U2 - 10.1016/S0014-4886(03)00044-X

DO - 10.1016/S0014-4886(03)00044-X

M3 - Article

VL - 181

SP - 213

EP - 223

JO - Experimental Neurology

JF - Experimental Neurology

SN - 0014-4886

IS - 2

ER -